Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw
Objective: Intravenous zoledronic acid (ZA) is often replaced with subcutaneous denosumab in patients with bone metastatic cancer. Despite their different pharmacologic mechanisms of action, both denosumab and ZA are effective in bone metastasis but cause osteonecrosis of the jaw (ONJ) as a side eff...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Mosby Inc.
2018
|
| Subjects: | |
| Online Access: | View Fulltext in Publisher |
